On Wednesday, U.S. Food and Drug Administration FDA approved Eli Lilly's GLP-1 receptor agonist, Zepbound, as a weight loss treatment. The injection, tirzepatide, will be approved in the U.S. for chronic weight management in adults with obesity or overweight, including those with weight-related conditions like diabetes, the regulator stated. Lilly confirmed that Zepbound, a once-weekly subcutaneous injection, will be available for U.S. customers by year-end, offering six doses starting at 2.5 mg. Priced at $1,059.87 per month, it reflects a 20% reduction compared to Novo's 2.4 mg weight loss injection, semaglutide.

Related Videos :







Eli Lilly secures FDA clearance for weight loss treatment #LLY #EliLillyStock #LLYStock [UK6jCgLdE]

Eli Lilly secures FDA clearance for weight loss treatment #LLY #EliLillyStock #LLYStock [UK6jCgLdE]

On Wednesday, U.S. Food and Drug Administration FDA approved Eli Lilly's GLP-1 receptor agonist, Zepbound, as a weight loss treatment. The injection, tirzepatide, will be approved in the U.S. for chronic weight management in adults with obesity or overweight, including those with weight-related conditions like diabetes, the regulator stated. Lilly confirmed that Zepbound, a once-weekly subcutaneous injection, will be available for U.S. customers by year-end, offering six doses starting at 2.5 mg. Priced at $1,059.87 per month, it reflects a 20% reduction compared to Novo's 2.4 mg weight loss injection, semaglutide.

Related Videos :

Aired: December 3rd 2024

Rating: TV-14

Buy Now:

Problems Playing Video? | Closed Captioning

Learn About Midwifery Today

Blog

Learn About Midwifery Today

Read the Modern Day Midwives Blog and learn more about our bloggers, all experienced midwives.

Read now